rosiglitazone has been researched along with Electron Transport Chain Deficiencies, Mitochondrial in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Acherjee, T; Ballabh, P; Cheng, B; Deo, A; Iacobas, DA; Krishna, S; Mamtani, S; Shah, E; Sharma, DR; Stempinski, ES; Thomas, T; Yadav, S; Zhang, J; Zhang, X | 1 |
| Cheng, YC; Chiang, MC; Lin, CH; Lin, KH; Nicol, CJ; Yen, CH | 1 |
2 other study(ies) available for rosiglitazone and Electron Transport Chain Deficiencies, Mitochondrial
| Article | Year |
|---|---|
PPAR-γ activation enhances myelination and neurological recovery in premature rabbits with intraventricular hemorrhage.
Topics: Amino Acid Transport Systems, Acidic; Animals; Animals, Newborn; Antiporters; Cerebral Intraventricular Hemorrhage; Disease Models, Animal; Hereditary Central Nervous System Demyelinating Diseases; Humans; Infant, Premature; Microglia; Mitochondrial Diseases; Myelin Proteins; Oligodendroglia; PPAR gamma; Psychomotor Disorders; Rabbits; Rosiglitazone; Sequence Analysis, RNA | 2021 |
Rosiglitazone activation of PPARγ-dependent pathways is neuroprotective in human neural stem cells against amyloid-beta-induced mitochondrial dysfunction and oxidative stress.
Topics: Amyloid beta-Peptides; Cells, Cultured; Humans; Mitochondrial Diseases; Neural Stem Cells; Neuroprotective Agents; Oxidative Stress; PPAR gamma; Rosiglitazone; Signal Transduction; Thiazolidinediones | 2016 |